Trial Profile

A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gunagratinib (Primary)
Indications Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors InnoCare Pharma

12 Mar 2023 Planned End Date changed from 16 Feb 2023 to 15 Apr 2024.
12 Mar 2023 Planned primary completion date changed from 21 Oct 2022 to 30 Nov 2023.
05 Jan 2023 According to InnoCare Pharma media release, data from phase IIa dose-expansion study will be presented at at the 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com